Document is current

Article History

Received: 18 April 2024

Accepted: 28 January 2025

First Online: 3 March 2025

Competing interests

: C.J.L. makes the following disclosures: he receives and/or has received research funding from AstraZeneca, Merck KGaA and Artios; received consultancy, SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline Dawn Bioventures, Blacksmith Medicines and FoRx; has stock in Tango, Ovibio, Hysplex, Tesselate and Ariceum. He is also a named inventor on patents describing the use of DNA-repair inhibitors, including ATR inhibitors, and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also reports benefits from this scheme associated with patents for PARP inhibitors, paid into C.J.L.’s personal account and research accounts at the Institute of Cancer Research. A.N.J.T. is or has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer, Vertex, GE Healthcare, Inbiomotion, Prime Oncology, Medscape Education, EMPartners, VJ Oncology, Gilead and MD Anderson Cancer Center, has received grant or research support from AstraZeneca, Myriad, Medivation and Merck KGaA, is a stockholder in Inbiomotion, is also a named inventor on patents describing the use of DNA-repair inhibitors, and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid to A.N.J.T.’s research accounts at the ICR. The other authors declare no competing interests.